dm1 — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T16899	SMCC-DM1	DM1-SMCC	Others
	SMCC-DM1 (DM1-SMCC) (DM1-SMCC) is a drug-linker conjugate which composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody-drug conjugate (ADC).		Others
T21408	DM1-SMe	DM1-SSMe	Microtubule Associated
	DM1-SMe (DM1-SSMe) is a potent inhibitor of maytansinoid microtubular. DM1-SMe is about 3 to 10-fold more potent than the parent drug Maytansine, with IC50s of 0.003 to 0.01 nM for DM1-SMe in a panel of human tumor cell ...		Microtubule Associated
T11917	Lys-SMCC-DM1	Lys-Nε-MCC-DM1	Microtubule Associated
	DM1 is a tubulin inhibitor. Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is the active metabolite of DM1.		Microtubule Associated
T38788	MC-DM1	MC-DM1
	MC-DM1 is a drug-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker MC to make antibody drug conjugate (ADC).
T38493	MCC-DM1	MCC-DM1
	MCC-DM1 is a drug-Linker Conjugates for ADC such ad Anti-CD22-MCC-DM1.
T24007	DM1-MCC	MCC-DM1	Others
	DM1-MCC (MCC-DM1) is an anticancer drug DM1 with an MCC linker.		Others
T1992	Mertansine	DM1,Maytansinoid DM1	Microtubule Associated
	Mertansine (DM1) refers to the thiol-containing maytansinoid, DM1 (N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) attached to a monoclonal antibody through reaction of the thiol group with the SPP (N-succinimidyl 4...		Microtubule Associated
T18718	SPP-DM1		Others
	SPP-DM1, a drug-linker conjugate for antibody-drug conjugates (ADC), demonstrates potent antitumor activity. It comprises DM1 (a potent microtubule-disrupting agent) connected through the ADC linker SPP[1].		Others
T12805	S-methyl DM1		Microtubule Associated
	S-methyl DM1 is a thiomethyl derivative of Maytansine. S-methyl DM1 binds to tubulin(Kd of 0.93 μM) and inhibts microtubule polymerization.		Microtubule Associated
T17832	DM1-PEG4-DBCO		Others
	DM1-(PEG)4-DBCO is a drug-linker conjugate that combines the potent microtubulin inhibitor mertansine (DM1) with the DBCO-PEG4-Ahx linker for the development of antibody-drug conjugates (ADCs). This conjugation aims to m...		Others
T17793	DBCO-PEG4-Ahx-DM1		Others
	DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate that combines the microtubulin inhibitor DM1 (mertansine), which is an antibody-conjugatable maytansinoid designed to reduce systemic toxicity and improve tumor-specific deliv...		Others
T18678	SC-VC-PAB-DM1		Others
	SC-VC-PAB-DM1 is a drug-linker conjugate utilized in Antibody-Drug Conjugates (ADC), featuring DM1 (Mertansine, a tubulin inhibitor) linked through the SC-VC-PAB[1] ADC linker to deliver potent antitumor activity.		Others
T18305	Mal-VC-PAB-DM1		Others
	Mal-VC-PAB-DM1, a drug-linker conjugate for antibody-drug conjugates (ADCs), exhibits potent antitumor activity. It incorporates DM1, a potent microtubule-disrupting agent, connected through the ADC linker Mal-VC-PAB [1]...		Others
T77848	Vc-PABC-DM1
	vc-PABC-DM1 is a chemical compound utilized for the synthesis of an antibody-drug conjugate (ADC) that incorporates a disulfide linker. This compound is instrumental in investigating serum stability [1].
T5541	PDM11	1-[2-(4-Chloro-phenyl)-vinyl]-3,5-diMeth,PDM 11	AhR
	PDM11 (1-[2-(4-Chloro-phenyl)-vinyl]-3,5-diMeth) is an antagonist of aryl hydrocarbon receptor (AhR)		AhR
T25141	BDM14471	BDM-14471,BDM 14471
	BDM14471 is a selective inhibitor of hydroxamate PfAM1.
T68612	DM175
	DM175 is a novel partial FXR agonist, causing specific modulatory effects on FXR activity that clearly differ from classical FXR agonists.
T62405	KDM1/CDK1-IN-1
	KDM1/CDK1-IN-1 (compound 4) is a potent inhibitor of KDM1 (IC50: 0.096 μM) and CDK1 (IC50: 0.078 μM). kDM1/CDK1-IN-1 blocks the cell cycle of HOP-92 cells in G2/M phase and induces apoptosis. KDM1/CDK1-IN-1 is highly cyt...
T80721	Zndm19
	Zndm19 is an inhibitor of New Delhi Metallo-β-lactamase-1 (NDM-1), utilized in researching drug-resistant bacterial infections [1].
T28235	OMDM169	OMDM 169,OMDM-169
	OMDM169 is a potent and selective MAGL inhibitor. OMDM169 could enhances 2-AG levels and of exerts analgesic activity via indirect activation of cannabinoid receptors. OMDM169 exhibited 0.13 microM1 microM tow...